Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)

SHA:688076 Revenue

Jiangsu Sinopep-Allsino Biopharmaceutical had revenue of 586.67M CNY in the quarter ending June 30, 2026, with 21.55% growth. This brings the company's total for the last twelve months to 2.03B, up 10.46% year-over-year. In the year 2025, Jiangsu Sinopep-Allsino Biopharmaceutical had annual revenue of 1.94B with 19.57% growth. That makes Jiangsu Sinopep-Allsino Biopharmaceutical the 14,431st largest company in the world by revenue and 2,572nd in China.

• Revenue (ttm): 2.03B
• Revenue Growth: +10.46%
• P/S Ratio: 4.24
• Revenue / Employee: 861.94K
• Employees: 2,360
• Market Cap: 8.66B

Revenue Chart

Chart

Chart

Revenue by Geography

Chart

• Overseas 1.37B 70.3%
• China 576.96M 29.7%

Fiscal year ended Dec 31, 2025 See the full SHA:688076 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.94B	318.00M	19.57%
Dec 31, 2024	1.62B	591.25M	57.21%
Dec 31, 2023	1.03B	382.26M	58.69%
Dec 31, 2022	651.29M	7.42M	1.15%
Dec 31, 2021	643.87M	77.00M	13.58%

Data Source: S&P Global Market Intelligence Last updated: Aug 25, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 22, 2026

Data Sources Report a data error